Literature DB >> 6507242

Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow.

C V Leier, T J Patrick, J Hermiller, K D Pacht, P Huss, R D Magorien, D V Unverferth.   

Abstract

Ten patients with moderate to severe congestive heart failure (CHF) underwent central and regional hemodynamic measurements at rest and central hemodynamic measurements during exercise before and after the oral administration of nifedipine (0.2 mg/kg). Nifedipine significantly decreased systemic blood pressure, systemic vascular resistance, pulmonary artery pressure, pulmonary vascular resistance, and pulmonary capillary wedge pressure. Stroke volume and cardiac output increased after nifedipine. The measured parameters of left ventricular inotropy did not change significantly for this calcium channel blocker. While blood flow to renal, hepatic, and limb vascular beds increased (p less than 0.05 for renal and limb) after nifedipine, only limb blood flow increased in proportion to the increase in cardiac output, suggesting preferential dilatation of limb vasculature. Although initial-dose nifedipine did not increase exercise duration, it elicited an improvement in exercise hemodynamics by reducing systemic vascular resistance and pulmonary capillary wedge pressure and increasing stroke volume and cardiac output. The calcium channel blocker, nifedipine, can be administered safely in the setting of ventricular failure and appears to favorably alter resting and exercise hemodynamics. A select number of patients with CHF may benefit from its long-term administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507242     DOI: 10.1016/0002-8703(84)90693-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

Review 3.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

4.  Effect of nifedipine on plasma catecholamines in man at rest and during exercise.

Authors:  G Defer; Y C Guezennec; F Lhoste
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  [Calcium antagonists in heart failure?].

Authors:  H Drexler; H Just
Journal:  Klin Wochenschr       Date:  1986-10-15

6.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 7.  Clinical pharmacokinetics of nicotine.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

8.  [Increase in liver circulation with nifedipine].

Authors:  J Nitsch; R Kuhnen; B Lüderitz
Journal:  Klin Wochenschr       Date:  1986-10-31

9.  Haemodynamic effects of felodipine in congestive heart failure.

Authors:  P Held; K Swedberg
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 10.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.